Eradication of H. Pylori With the Regimen Individualized Susceptibility of H. Pylori to Clarithromycin Determined by the Mutation of 23S rRNA of H. Pylori
Phase 2
- Conditions
- patients infected with H. pylori
- Registration Number
- JPRN-UMIN000022766
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
nder progression
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
Patients allergic to the any of the drugs used for eradication of H. pylori. Patients who do not agree to the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication rates of H. pylori is assessed bythe 13C-urea breath test performed at 1 month after the therapy.
- Secondary Outcome Measures
Name Time Method interview on the adverse events during the treatment, such as diarrhea, loose stool, abdominal pain and allergic reactions.